Chemomab Therapeutics Engaging Investors
Chemomab Therapeutics Ltd. (CMMB) is gearing up for two significant investor conferences where they will highlight their latest advancements. As a clinical-stage biotech company, Chemomab specializes in developing innovative therapies targeting fibro-inflammatory diseases that currently lack effective treatments.
Upcoming Investor Conferences
The management team at Chemomab will meet with investors at the Third Annual ROTH Healthcare Opportunities Conference, taking place in New York City on October 9, 2024. This is a valuable opportunity for the company to communicate their vision and share insights into their product pipeline.
Details of the ROTH Conference
This invitation-only event will feature one-on-one meetings where investors can discuss the company's potential further. The format of the conference allows for personalized interactions, offering a platform for Chemomab’s leadership to articulate their strategic direction and growth plans.
Maxim Healthcare Virtual Summit
Following the ROTH conference, Chemomab’s co-founder and CEO, Dr. Adi Mor, will participate in a fireside chat during the Maxim Healthcare Virtual Summit scheduled for October 16, 2024. This session will provide insights into the company's clinical focus and the progress of their lead product.
Fireside Chat Insights
The Maxim summit will be accessible virtually, allowing a broader audience to engage with Dr. Mor's presentation. A recording of this chat will be available on Chemomab's investor relations website, ensuring that those who could not attend can still receive key information.
Introduction to Chemomab's Core Therapeutics
Chemomab is deeply committed to addressing severe fibro-inflammatory diseases with a notable unmet need. Their lead product, CM-101, is a promising therapeutic candidate that targets the protein CCL24, known for its role in fibrosis and inflammation. Early studies have shown that CM-101 not only maintains a favorable safety profile but also could potentially treat multiple severe conditions.
Advancements with CM-101
Recently, Chemomab reported encouraging results from its Phase 2 trial focusing on primary sclerosing cholangitis (PSC), a rare liver disorder. This has set the stage for pivotal milestones in 2025, including feedback from the FDA regarding the company’s plans for a Phase 3 registration trial. The company has achieved significant designations, such as Orphan Drug and Fast Track status, which bolster their development initiatives.
Future Prospects of Chemomab
Chemomab is not only focusing on PSC but is also preparing CM-101 for systemic sclerosis treatment, which has now reached Phase 2 readiness with an active IND in the U.S. This dual-path approach highlights the company’s versatility and dedication to addressing various fibro-inflammatory diseases.
Contact Information
For inquiries and more information, media representatives can contact Barbara Lindheim, the Consulting Vice President for Investor and Public Relations at Chemomab. She is reachable at +1 917-355-9234 or via email at barbara.lindheim@chemomab.com. Additionally, general investor-related questions can be directed to IR@chemomab.com.
Frequently Asked Questions
What is Chemomab Therapeutics known for?
Chemomab Therapeutics is a biotechnology company focused on developing therapeutics for fibro-inflammatory diseases.
When will Chemomab participate in investor conferences?
Chemomab will be attending investor conferences on October 9 and October 16, 2024.
Who is leading Chemomab's participation in the conferences?
Dr. Adi Mor, Chemomab's CEO, will notably participate in a fireside chat during the Maxim Healthcare Virtual Summit.
What is CM-101?
CM-101 is Chemomab's lead therapy targeting the protein CCL24 for treating fibro-inflammatory diseases.
How can investors stay updated on Chemomab's progress?
Investors can access presentations and recordings on Chemomab's investor relations website for updates.
